{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:10Z","timestamp":1787702410696,"version":"build-2784847793"},"reference-count":34,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This observational study describes the real-world economic burden in patients with anaplastic lymphoma kinase ( ALK) positive non-small cell lung cancer (NSCLC) receiving a first-line ALK inhibitor, and the economic impact of brain metastases (BM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Administrative claims data (Truven Health MarketScan\u00ae Commercial Claims and Encounters database and Medicare Supplemental and Coordination of Benefits database; January 1, 2015\u2013March 31, 2020) for adult patients with ALK+ NSCLC who received a first-line ALK inhibitor were retrospectively reviewed. Healthcare costs and resource utilization were calculated on a per-patient-per-month (PPPM) basis and stratified by the presence or absence of BM prior to first-line ALK inhibitor. Factors associated with costs were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 496 patients were eligible for analysis. Mean PPPM total healthcare costs were $21,961 for all patients receiving up to 1 year of a first-line ALK inhibitor. Patients were significantly more likely to have higher mean PPPM total costs if they had BM prior to first-line ALK inhibitor (vs. no BM; odds ratio: 1.11; 95% confidence interval: 1.02, 1.21; p\u2009=\u20090.013). Mean PPPM days of hospital stay ( p\u2009=\u20090.0056), and inpatient hospital visits ( p\u2009=\u20090.0030) were significantly higher for patients with BM compared to no BM. The main cost drivers for non-inpatient procedures for all patients were medications, radiation therapy, and other diagnostic procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The economic burden in patients with ALK+ NSCLC receiving a first-line ALK inhibitor was high. Patients with ALK+ NSCLC and BM had higher healthcare costs and resource utilization than patients without BM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221126174","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T01:00:10Z","timestamp":1663808410000},"page":"1418-1427","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Economic burden in patients with anaplastic lymphoma kinase (\n                    <i>ALK<\/i>\n                    )-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors"],"prefix":"10.1177","volume":"29","author":[{"given":"Yanyu","family":"Wu","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Ren","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wan","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamao M","family":"Lin","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"bibr1-10781552221126174","unstructured":"Globocan. International Agency for Research on Cancer. World Health Organization. Lung fact sheet, https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/15-Lung-fact-sheet.pdf (2020, accessed 29 September 2021)."},{"key":"bibr2-10781552221126174","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.06.07"},{"key":"bibr3-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0318"},{"key":"bibr4-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0168"},{"key":"bibr5-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24181"},{"key":"bibr6-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6993"},{"key":"bibr7-10781552221126174","unstructured":"Roche. FDA approves Roche\u2019s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer, https:\/\/www.roche.com\/media\/releases\/med-cor-2017-11-07.htm (2017, accessed 3 February 2022)."},{"key":"bibr8-10781552221126174","unstructured":"Takeda. U.S. FDA Approves Takeda\u2019s ALUNBRIG\u00ae (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer, https:\/\/www.takeda.com\/newsroom\/newsreleases\/2020\/u.s.fda-approves-takedas-alunbrig-brigatinib-as-a-first-line-treatment-option-for-patients-diagnosed-with-rare-and-serious-form-of-lung-cancer (2020, accessed 3 February 2022)."},{"key":"bibr9-10781552221126174","unstructured":"Pfizer. U.S. FDA Expands Approval of Pfizer\u2019s Lorbrena\u00ae as First-Line Treatment for ALK-Positive Metastatic Lung Cancer, https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-expands-approval-pfizers-lorbrenar-first-line (2021, accessed 3 February 2022)."},{"key":"bibr10-10781552221126174","unstructured":"Novartis. Novartis receives FDA approval for expanded use of Zykadia\u00ae in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC), https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-expanded-use-zykadia-first-line-alk-positive-metastatic-non-small-cell-lung-cancer-nsclc (2017, accessed 3 February 2022)."},{"key":"bibr11-10781552221126174","unstructured":"Pfizer. U.S. Food and Drug Administration Approves Pfizer\u2019s Xalkori\u00ae (Crizotinib) as First and Only Therapy Specifically for Patients With Locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer, https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_food_and_drug_administration_approves_pfizer_s _xalkori_crizotinib_as_first_and_only_therapy_specifically_for_patients_with_locally_advanced_or_metastatic_alk_positive_non_small_cell_lung_cancer (2011, accessed 3 February 2022)."},{"key":"bibr12-10781552221126174","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V1.2022.\n                      \u00a9\n                      National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed February 9, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"bibr13-10781552221126174","doi-asserted-by":"publisher","DOI":"10.17925\/EOH.2020.16.1.18"},{"key":"bibr14-10781552221126174","doi-asserted-by":"publisher","DOI":"10.3390\/cancers2042100"},{"key":"bibr15-10781552221126174","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26073"},{"key":"bibr16-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.009"},{"key":"bibr17-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1159\/000502755"},{"key":"bibr18-10781552221126174","doi-asserted-by":"publisher","DOI":"10.3390\/ph13120474"},{"key":"bibr19-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2019.03.009"},{"key":"bibr20-10781552221126174","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00557"},{"key":"bibr21-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0539"},{"key":"bibr22-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz260"},{"key":"bibr23-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy405"},{"key":"bibr24-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.035"},{"key":"bibr25-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187"},{"key":"bibr26-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.03.007"},{"key":"bibr27-10781552221126174","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.1003644"},{"key":"bibr28-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1762620"},{"key":"bibr29-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.03.008"},{"key":"bibr30-10781552221126174","volume-title":"IBM MarketScan research databases for health services researchers. A white paper","author":"Hansen L","year":"2021"},{"key":"bibr31-10781552221126174","unstructured":"SAS \u2013 today and tomorrow. (Version 9.4). [Software], https:\/\/support.sas.com\/software\/94 2021."},{"key":"bibr32-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e14046"},{"key":"bibr33-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1057115"},{"key":"bibr34-10781552221126174","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2018.1445092"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221126174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221126174","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221126174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:33Z","timestamp":1777688853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221126174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/10781552221126174"],"URL":"https:\/\/doi.org\/10.1177\/10781552221126174","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}